Code | CSB-MP011649HU3 |
Abbreviation | Recombinant Human IL2RA protein, partial (Active) |
MSDS | |
Size | $118 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
The recombinant human interleukin-2 receptor subunit alpha (IL2RA) is generated in the mammalian cell expression system. The gene encoding the human IL2RA protein (22-213aa) is inserted into a plasmid vector, along with a C-terminal 10xHis-tag gene. This recombinant vector is transfected into mammalian cells. The transfected cells are cultured under controlled conditions that promote protein expression. The recombinant human IL2RA protein is harvested from the cell culture media. Its purity was measured to be greater than 95% using SDS-PAGE. The endotoxin content of this protein was determined to be less than 1.0 EU/ug using the LAL method. It reacted with both IL2RA recombinant antibody (CSB-RA011649MA1HU) and human IL2 (CSB-MP011629HU), demonstrating its bioactivity.
IL2RA, a specific component of the high-affinity IL2R, is primarily expressed on the surface of activated T cells, B cells, subsets of thymic cells, pre-B cells, and Treg cells. IL2RA exhibits high expression on the surface of various hematological tumor cells and is associated with tumor prognosis. Moreover, the elevated expression of IL2RA on activated circulating immune cells and Treg cells has been utilized in IL-2 immunotherapy for treating tumors and autoimmune diseases. Currently, the administration of anti-IL2RA radioimmunoconjugates and immunotoxins has been established as relatively clinically safe and effective in various hematological tumor indications. Additionally, novel antibody-drug conjugates (ADCs) targeting IL2RA are actively undergoing clinical trials. Developing mammalian IL2RA protein with high activity holds significant importance in facilitating research on IL2RA-related drugs.
There are currently no reviews for this product.